Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 4

NCT ID: NCT02235974 Enrolling by invitation - Stroke Clinical Trials

Critical Periods After Stroke Study (CPASS)

CPASS
Start date: August 26, 2014
Phase: N/A
Study type: Interventional

To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive motor training. The investigators will perform a prospective exploratory study of upper extremity (UE) motor training delivered at higher than usual intensity at three different time points after stroke: - early (initiated within 30 days) - subacute/outpatient (initiated within 2-3 months) - chronic (initiated within 6-9 months) The control group will not receive the therapy intervention during the 1-year study. Outcome measures will be assessed at baseline, pre-treatment, post-treatment, 6 months and one year after stroke onset. Compared to individuals randomized during the outpatient (2-3 months after stroke onset) or chronic (6-9 months after stroke onset) time points, participants randomized to early intensive motor training will show greater upper extremity motor improvement measured at one year post stroke.

NCT ID: NCT02033681 Enrolling by invitation - Ischemia Clinical Trials

Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution

Start date: September 2013
Phase: N/A
Study type: Interventional

The aim of this study is to know the characteristic of "one-per-mil" tumescent solution in regards of the optimal time delay to achieve optimal visualization of operation field in hand and digit surgery. Hypothesis: 1. Epinephine in "one-per-mil" concentration by tumescent injection technique will provide faster decrease in oxygen saturation compared to normal saline solution injected by tumescent technique. 2. Epinephrine in "one-per-mil" concentration by tumescent injection technique will provide effectiveness in vasoconstriction longer than 10 minutes as the optimal time delay. 3. Epinephine in "one-per-mil" concentration by tumescent injection technique causes no finger necrosis as normal saline solution injected by tumescent technique.

NCT ID: NCT01979965 Enrolling by invitation - Clinical trials for Ischemic Mitral Regurgitation

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

REIN-MR
Start date: November 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.

NCT ID: NCT01979367 Enrolling by invitation - Clinical trials for Lower Extremity Swelling Acute

Physician Clinical Trial Policy (CTP) Neurological Ischemia Lower Extremity Pain and Swelling

DTSC
Start date: March 2012
Phase: N/A
Study type: Interventional

Physician Clinical Trial Policy (CTP) to evaluate the efficacy treatment of lower extremity pathologies derived from neurological ischemia disorders using the combination of Monochromatic Infrared Photo Energy (MIRE) and Transcutaneous Electrical Nerve Stimulation (TENS) therapies.

NCT ID: NCT01925872 Enrolling by invitation - Clinical trials for Ischemic Cerebrovascular Disease

Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance

ORETCR
Start date: May 2013
Phase: N/A
Study type: Observational

1. Clopidogrel resistance is common in patients of ischemic cerebrovascular disease. 2. Genetic polymorphisms are the most important factors to clopidogrel resistance. 3. The purpose of this study is to find the genes which are the related to clopidogrel resistance. 4. Through gene sequencing, we can filter patient of clopidogrel resistance, so another drug maybe used to avoid the undesired efficacy.

NCT ID: NCT01709279 Enrolling by invitation - Clinical trials for Ischemic Heart Failure

Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Start date: August 2012
Phase: N/A
Study type: Interventional

Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible ischemic heart failure patients will be proceeded intracoronary administration of autologous adipose tissue derived stromal cells by cardiac catheterization.